Targeting PCSK9 for therapeutic gains

Have we addressed all the concerns?

Yajnavalka Banerjee, Raul D. Santos, Khalid Al-Rasadi, Manfredi Rizzo

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) regulates the expression of low-density lipoprotein (LDL)-receptors, through reducing their recycling by binding to the receptor along with LDL and targeting it for lysosomal destruction. PCSK9 also enhances the degradation of very-low-density-lipoprotein receptor (VLDLR) and lipoprotein receptor-related protein 1 (LRP-1) in a LDL-receptor independent manner. This role in lipid homeostasis presents PCSK9 as an attractive target for the therapeutic management of familial hypercholesterolemia as well as other refractory dyslipidaemias. However, PCSK9 mediates multifarious functions independent of its role in lipid homeostasis, which can be grouped under "pleiotropic functions" of the protein. This includes PCSK9's role in: trafficking of epithelial sodium channel; hepatic regeneration; pancreatic integrity and glucose homeostasis; antiviral activity; antimalarial activity; regulation of different cell signalling pathways; cortical neural differentiation; neuronal apoptosis and Alzheimer's disease. The question that needs to be investigated in depth is "How will the pleotropic functions of PCSK9, be affected by the therapeutic intervention of the protease's LDL-receptor lowering activity?" In this review, we appraise the different lipid lowering strategies targeting PCSK9 in light of the protein's different pleiotropic functions. Additionally, we delineate the key areas that require further examination, to ensure the long-term safety of the above lipid-lowering strategies.

Original languageEnglish
Pages (from-to)62-75
Number of pages14
JournalAtherosclerosis
Volume248
DOIs
Publication statusPublished - May 1 2016

Fingerprint

LDL Receptors
Lipids
Homeostasis
Therapeutics
Lipoprotein Receptors
Epithelial Sodium Channels
Hyperlipoproteinemia Type II
Proteins
Antimalarials
Recycling
Dyslipidemias
LDL Lipoproteins
Antiviral Agents
Proprotein Convertase 9
Regeneration
Alzheimer Disease
Peptide Hydrolases
Apoptosis
Safety
Glucose

Keywords

  • Adnectin
  • Anti-sense oligonucleotide
  • CRISPR-CAS9
  • LDL-C
  • LDL-receptor
  • Lipoprotein-apheresis
  • Monoclonal antibody
  • PCSK9
  • PCSK9-Centric lipid lowering
  • Peptide-mimetic
  • Pleiotropic
  • Vaccine
  • VLDL

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Targeting PCSK9 for therapeutic gains : Have we addressed all the concerns? / Banerjee, Yajnavalka; Santos, Raul D.; Al-Rasadi, Khalid; Rizzo, Manfredi.

In: Atherosclerosis, Vol. 248, 01.05.2016, p. 62-75.

Research output: Contribution to journalArticle

Banerjee, Yajnavalka ; Santos, Raul D. ; Al-Rasadi, Khalid ; Rizzo, Manfredi. / Targeting PCSK9 for therapeutic gains : Have we addressed all the concerns?. In: Atherosclerosis. 2016 ; Vol. 248. pp. 62-75.
@article{3070793e5827447081c363f1f7f6ce54,
title = "Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?",
abstract = "Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) regulates the expression of low-density lipoprotein (LDL)-receptors, through reducing their recycling by binding to the receptor along with LDL and targeting it for lysosomal destruction. PCSK9 also enhances the degradation of very-low-density-lipoprotein receptor (VLDLR) and lipoprotein receptor-related protein 1 (LRP-1) in a LDL-receptor independent manner. This role in lipid homeostasis presents PCSK9 as an attractive target for the therapeutic management of familial hypercholesterolemia as well as other refractory dyslipidaemias. However, PCSK9 mediates multifarious functions independent of its role in lipid homeostasis, which can be grouped under {"}pleiotropic functions{"} of the protein. This includes PCSK9's role in: trafficking of epithelial sodium channel; hepatic regeneration; pancreatic integrity and glucose homeostasis; antiviral activity; antimalarial activity; regulation of different cell signalling pathways; cortical neural differentiation; neuronal apoptosis and Alzheimer's disease. The question that needs to be investigated in depth is {"}How will the pleotropic functions of PCSK9, be affected by the therapeutic intervention of the protease's LDL-receptor lowering activity?{"} In this review, we appraise the different lipid lowering strategies targeting PCSK9 in light of the protein's different pleiotropic functions. Additionally, we delineate the key areas that require further examination, to ensure the long-term safety of the above lipid-lowering strategies.",
keywords = "Adnectin, Anti-sense oligonucleotide, CRISPR-CAS9, LDL-C, LDL-receptor, Lipoprotein-apheresis, Monoclonal antibody, PCSK9, PCSK9-Centric lipid lowering, Peptide-mimetic, Pleiotropic, Vaccine, VLDL",
author = "Yajnavalka Banerjee and Santos, {Raul D.} and Khalid Al-Rasadi and Manfredi Rizzo",
year = "2016",
month = "5",
day = "1",
doi = "10.1016/j.atherosclerosis.2016.02.018",
language = "English",
volume = "248",
pages = "62--75",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Targeting PCSK9 for therapeutic gains

T2 - Have we addressed all the concerns?

AU - Banerjee, Yajnavalka

AU - Santos, Raul D.

AU - Al-Rasadi, Khalid

AU - Rizzo, Manfredi

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) regulates the expression of low-density lipoprotein (LDL)-receptors, through reducing their recycling by binding to the receptor along with LDL and targeting it for lysosomal destruction. PCSK9 also enhances the degradation of very-low-density-lipoprotein receptor (VLDLR) and lipoprotein receptor-related protein 1 (LRP-1) in a LDL-receptor independent manner. This role in lipid homeostasis presents PCSK9 as an attractive target for the therapeutic management of familial hypercholesterolemia as well as other refractory dyslipidaemias. However, PCSK9 mediates multifarious functions independent of its role in lipid homeostasis, which can be grouped under "pleiotropic functions" of the protein. This includes PCSK9's role in: trafficking of epithelial sodium channel; hepatic regeneration; pancreatic integrity and glucose homeostasis; antiviral activity; antimalarial activity; regulation of different cell signalling pathways; cortical neural differentiation; neuronal apoptosis and Alzheimer's disease. The question that needs to be investigated in depth is "How will the pleotropic functions of PCSK9, be affected by the therapeutic intervention of the protease's LDL-receptor lowering activity?" In this review, we appraise the different lipid lowering strategies targeting PCSK9 in light of the protein's different pleiotropic functions. Additionally, we delineate the key areas that require further examination, to ensure the long-term safety of the above lipid-lowering strategies.

AB - Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) regulates the expression of low-density lipoprotein (LDL)-receptors, through reducing their recycling by binding to the receptor along with LDL and targeting it for lysosomal destruction. PCSK9 also enhances the degradation of very-low-density-lipoprotein receptor (VLDLR) and lipoprotein receptor-related protein 1 (LRP-1) in a LDL-receptor independent manner. This role in lipid homeostasis presents PCSK9 as an attractive target for the therapeutic management of familial hypercholesterolemia as well as other refractory dyslipidaemias. However, PCSK9 mediates multifarious functions independent of its role in lipid homeostasis, which can be grouped under "pleiotropic functions" of the protein. This includes PCSK9's role in: trafficking of epithelial sodium channel; hepatic regeneration; pancreatic integrity and glucose homeostasis; antiviral activity; antimalarial activity; regulation of different cell signalling pathways; cortical neural differentiation; neuronal apoptosis and Alzheimer's disease. The question that needs to be investigated in depth is "How will the pleotropic functions of PCSK9, be affected by the therapeutic intervention of the protease's LDL-receptor lowering activity?" In this review, we appraise the different lipid lowering strategies targeting PCSK9 in light of the protein's different pleiotropic functions. Additionally, we delineate the key areas that require further examination, to ensure the long-term safety of the above lipid-lowering strategies.

KW - Adnectin

KW - Anti-sense oligonucleotide

KW - CRISPR-CAS9

KW - LDL-C

KW - LDL-receptor

KW - Lipoprotein-apheresis

KW - Monoclonal antibody

KW - PCSK9

KW - PCSK9-Centric lipid lowering

KW - Peptide-mimetic

KW - Pleiotropic

KW - Vaccine

KW - VLDL

UR - http://www.scopus.com/inward/record.url?scp=84960439856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960439856&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2016.02.018

DO - 10.1016/j.atherosclerosis.2016.02.018

M3 - Article

VL - 248

SP - 62

EP - 75

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

ER -